Law360, New York (November 06, 2009) -- A group of paying customers has banded together in a newly amended complaint to accuse Boehringer Ingelheim International GmbH of prosecuting a patent it knew to be invalid in order to stymie generic-drug makers in their efforts to get cheaper versions of the Parkinson's drug Mirapex to market.
The putative class action, lodged Thursday in the U.S. District Court for the Western District of Pennsylvania, was filed two days after Judge Gary L. Lancaster gave the go-ahead with...
